Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODULATE: Nivolumab combinations in MSS CRC
NCT03647839Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Sep 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BNC105, napabucasin in metastatic colorectal cancer (mCRC), sponsored by Australasian Gastro-Intestinal Trials Group. Started Sep 2018; status: completed.
02
Drugs
BNC105napabucasin
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03647839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03647839.